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Abstract  
 
Triple-negative breast cancer (TNBC) is a heterogeneous disease and specific therapies have 
not been available for a long time. Therefore, conventional chemotherapy is still considered 
the clinical state-of-the-art. Different subgroups of TNBC have been identified based on 
protein expression, mRNA signatures and genomic alterations. Important elements of TNBC 
biology include a high proliferative activity, an increased immunological infiltrate, a basal-
like and a mesenchymal phenotype, and a deficiency in homologous recombination which is 
in part associated with loss of BRCA1/2 function. A minority show expression of luminal 
markers such as androgen receptors combined with a lower proliferative activity. These 
biological subgroups are overlapping and we are currently not able to combine them into a 
unified model of TNBC biology. Nevertheless, the molecular analysis of this disease has 
identified potential options for targeted therapeutic intervention. This has led to promising 
clinical strategies including modified chemotherapy approaches, DNA damage response 
targeting, angiogenesis inhibitors, immune checkpoint inhibitors, or even anti-androgens, 
that are currently evaluated in phase 1-3 clinical studies. The current review focusses on the 
most relevant clinical questions, summarizes the results of recent clinical trials and gives an 
overview on ongoing trials and current trial concepts that will lead to a more refined 
therapy of this tumor type. 
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Key messages:  
1. Triple-negative breast cancer (TNBC) should be regarded as a working category that,  
although useful for current clinical decisions, may have only limited value as a defined 
biological category for future targeted therapy approaches due to its “triple negative” 
definition.  
2. TNBCs are a highly heterogeneous group of tumors. Different approaches to classify these 
tumors have been established including classical pathology, mRNA expression profiling, DNA 
sequencing including analysis of copy number variations and structural rearrangements, and 
other molecular methods. 
3. Important parameters of TNBC biology, include a high proliferative activity, an increased 
immune cell infiltrate, a basal-like and a mesenchymal phenotype, a deficiency in 
homologous recombination partly linked to a loss of BRCA1 function, and an expression of 
androgen receptors. 
4. The different molecular phenotypes are observed in overlapping small subsets of TNBC, 
and there are non-TNBC tumors that may present with identical molecular characteristics. 
5. The current biological classifications do not allow a unified model of TNBC that can be 
introduced as a molecular diagnostic tool. 
6. Nevertheless, the increased knowledge on the molecular alterations in TNBC has led to 
several promising clinical approaches (including DNA damage response targeting, anti-
androgens and immune checkpoint inhibitors) that are currently evaluated in phase 2-3 
clinical studies and might lead to new treatment strategies. 
 
Search strategy and selection criteria:  
We searched the medline database for the search terms „(therapy) AND (((("triple negative 
breast neoplasms"[MeSH Terms] OR ("triple"[All Fields] AND "negative"[All Fields] AND 
"breast"[All Fields] AND "neoplasms"[All Fields]) OR "triple negative breast neoplasms"[All 
Fields] OR ("triple"[All Fields] AND "negative"[All Fields] AND "breast"[All Fields] AND 
"cancer"[All Fields]) OR "triple negative breast cancer"[All Fields])) AND ("2011/01/01"[Date 
- Publication] : "3000"[Date - Publication])))“. We largely selected publications in the past 5 
years, but did not exclude commonly referenced and highly regarded older publications. We 
also searched the reference lists of articles identified by this search strategy and selected 
those we judged relevant.  
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In addition, the abstracts of San Antonio Breast Cancer Symposium 2014 and 2015 and the 
ASCO Meeting 2015 and 2016 were reviewed for clinical trials with a focus on TNBC. 
Considering the fact that a large number of clinical trials in TNBC are currently ongoing, we 
focussed this clinical series on those trials with published results for most clinical strategies. 
Only for the new immune checkpoint inhibitor approaches, we have decided to include a 
table summarizing selected ongoing clinical trials. For other treatment strategies, we refer 
to published recent review articles that already provide an overview on ongoing clinical 
trials. 
It should be noted that some of the most recent trial results have been reported only as 
meeting abstracts and presentations, and a more comprehensive description of the results 
is expected upon publication of the full-papers in the upcoming months. Due to the large 
number of clinical trials for the different TNBC subtypes it was not possible to include all 
clinical trials in this review article, and the presentations was focussed on those trials that 
were most intensely discussed in the medical community, based on the judgement of the 
authors. For additional trials, review articles are cited to provide readers with more details 
and more references than this Seminar has room for.  
 
 
  
 5 
TNBC as a clinical problem 
Triple-negative breast cancer (TNBC) represents 15% of breast carcinomas and is defined by 
the absence of the three main breast cancer biomarkers, i.e. lack of expression of estrogen 
receptor (ER) and progesterone receptor (PR) as well as lack of amplification/overexpression 
of HER2.1 This negative definition together with biological and clinical heterogeneity has led 
authors to consider TNBC as “title of convenience” rather than a defined biological entity.2 
From a clinical perspective TNBC represents a highly relevant subgroup given that patients 
with TNBC do not benefit from endocrine or HER2-targeted agents and chemotherapy 
represents the only established therapeutic option.   
Considering the unfavorable prognosis and aggressive biology of TNBC3,4,5 many different 
experimental therapies are currently tested in phase 1 to 3 clinical studies. From these 
clinical studies, important response signals are emerging. Although the results of the new 
trials are of great interest, they should be interpreted with caution for patient-related 
clinical decisions because the current evidence is based mainly on small phase 1 or 2 trials 
or biomarker-driven analyses of subcohorts.  
 
Established chemotherapy strategies for TNBC 
Despite their unfavorable prognosis when regarded as a single group, many TNBCs are 
highly chemotherapy sensitive, and TNBCs have an increased neoadjuvant response rate 
compared to other breast cancer subtypes.6,7,8 This phenomenon (i.e. an improved chance 
of pathological complete response (pCR) in contrast to an overall unfavorable prognosis) is 
commonly referred to as “triple negative paradox.”9 It can be partly explained by the fact 
that highly-proliferating tumors have a poor prognosis and a high chance of response to 
chemotherapy at the same time. In addition, the poor prognosis of the group is driven by 
the very rapid onset of metastasis and poor prognosis of the TNBC subset that fail to 
respond to chemotherapy. 
Relevant chemotherapy trials and metaanalyses are summarized in table 1. The ETCBCG 
overview has shown that the relative chemotherapy benefit resulting in approximately one-
third reduction of breast cancer mortality is similar across breast cancer subtypes and 
independent of ER status.10 In neoadjuvant studies, the difference between overall survival 
of responders and non-responders is particularly high in the TNBC subgroup, as shown in a 
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comprehensive metaanalysis.11 In this metaanalysis the pCR rate for TNBC was 33.6%, and 
the hazard ratio (HR) for improved overall survival of pCR patients vs. non-responders was 
0.16 (95% CI 0.11–0.25) for the TNBC subgroup. Neoadjuvant approaches are therefore a 
central treatment strategy for TNBC.4,12 Standardized systems for measurement of 
neoadjuvant response and residual cancer burden have been published.13,14 In a 
metaanalysis of 3337 patients from 10 clinical studies, dose-dense therapy approaches were 
particularly effective in the HR-negative subgroup measured by immunohistochemistry.15 
However, this has not been observed in all clinical trials and it is also dependent on the 
selection and risk of the luminal tumors that are used for comparison as well as the method 
used for molecular classification.16  
 
Modified chemotherapy concepts including platinum compounds - new biomarker 
strategies 
Neoadjuvant approaches: The addition of platinum has been investigated as a promising 
approach for optimization of chemotherapy. In the GeparSixto trial, increased pCR rates17 
and improved survival rates18 with neoadjuvant carboplatin compared to a non-standard 
liposomal anthracycline and taxane control arm have been observed in the TNBC, but not in 
the HER2-pos subgroup. The increase in pCR caused by carboplatin was greater in a) 
patients without a BRCA1/2 mutation18 and b) patients with increased tumor-infiltrating 
lymphocytes.19 The homologous recombination deficiency (HRD) assay that has the aim to 
measure so-called genomic scars as indicators of HRD showed that HRD-assay high scoring 
tumors had higher pCR rates compared to HR-non-deficient tumors, but this was observed 
independent of treatment and the effect of carboplatin could not be predicted.20 In the 
CALGB 40603 trial, pCR rates in the overall TNBC trial population were improved with 
addition of neoadjuvant carboplatin (and bevacizumab),21 but the increased pCR rate was 
not linked to an improved survival of the experimental treatment groups.22 This is an 
example illustrating that pCR is an important prognostic parameter on a patient level, but 
not necessarily on a trial level. The Geicam 2006-03 trial has not shown any difference 
between pCR rates with neoadjuvant EC followed by docetaxel with or without carboplatin. 
This trial was restricted to an immunohistochemically defined basal-like subtype of TNBC 
and suggested no advantage to addition of platinum as an alkylating agent when patients 
had already received an alkylating agent regimen. In this trial the baseline treatment was 
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weaker in the carboplatin containing arm compared to the control arm.23 
Trials in the metastatic setting: In the CBCSG006 trial Hu et al. have reported in the 
metastatic setting in unselected advanced TNBC that the substitution of cisplatin for 
paclitaxel in the standard of care gemcitabine and paclitaxel regimen improved progression-
free survival.24 No a priori specified biological sub-group analyses were conducted.  
The phase 3 TNT trial has directly compared carboplatin vs. docetaxel in TNBC and patients 
with germline BRCA1/2 mutation and specified a priori biological subgroup analyses. In this 
trial, so far reported only as an abstract, the response to carboplatin therapy was not 
superior to that standard of care, docetaxel in the overall unselected TNBC group. The 
response to carboplatin was significantly greater than to docetaxel in patients with BRCA1/2 
mutated tumors, was similar to docetaxel in PAM50 basal-like cancers and was significantly 
inferior to docetaxel in the non-basal-like subtype, although the numbers in this non-basal-
like group were very small.25 The HRD-assay,26 identified a high score group with higher 
response rates in both therapy arms; but the score appeared not to predict platinum-
specific response. These data are supported by  previous non-randomized data in a phase 2 
trial of 20 patients with BRCA mutation and metastatic breast cancer that has reported an 
overall response rate of 80% with single-agent cisplatin therapy.27 Similarly, in the non-
randomized neo-adjuvant PreCOG 010528, and the non-randomized TBCRC009 trial29 in the 
metastatic setting, increased responses to platinum therapy were observed in the group of 
patients with BRCA mutations. In these trials as well as an additional analysis,30 response 
was also linked to higher HRD-assay scores. It should be noted that without a non-platinum 
control arm it is not possible to assess the specificity of the HRD-assay for platinum as 
opposed to standard of care therapy response, and additional investigations are required. 
Post-neoadjuvant strategies: In the post-neoadjuvant setting, the CREATE-X trial31 has 
reported that postneoadjuvant capecitabine leads to improved survival in poor-responders 
to neoadjuvant therapy. The TNBC subgroup (37% of patients) showed a hazard ratio (HR) of 
0.58 in favor of postneoadjuvant capecitabine treatment. The IBSCG 22-00 trial32 has 
investigated a metronomic maintenance therapy with cyclophosphamide and methotrexate 
after adjuvant or neoadjuvant chemotherapy. In the subgroup of nodal-positive TNBC a non-
significant trend for improved DFS was observed, which was not seen in the complete study 
cohort. 
Biomarker options for prediction of chemotherapy response: There are several reported 
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predictive factors for increased response to neoadjuvant chemotherapy. Most of these 
factors reflect the more aggressive phenotype, such as high grade, negative hormone 
receptor status and high proliferation rate.8 These factors are positive predictive factors for 
neoadjuvant response, but – at the same time – negative prognostic factors. Interestingly, 
immunological markers are often positively linked to both, increased neoadjuvant response 
as well as improved prognosis.33,34 These factors build a biological hypothesis for new 
therapeutic strategies, as shown below, but they are currently not used to stratify patients 
for clinical therapy decisions.  
Furthermore, there are no predictive markers that are significant across all different studies. 
For example, BRCA1/2 mutations are predictive for increased response to cisplatinum or 
carboplatin therapy in the metastatic setting in the TNT and TBCRC009 trial. In contrast in 
the neoadjuvant GeparSixto trial, patients with BRCA1/2 mutations had a higher response 
rate to the control therapy (but a lower increase in response rate with the addition of 
platinum therapy). In this trial a high response of treatment naïve patients with BRCA1/2 
mutations to control arm anthracycline/taxane based therapy appears to undermine any 
additional effect of platinum on response rates in a chemotherapy naïve primary treatment 
setting.  
 
Biologic and genomic alterations as a basis for new therapeutic strategies  
Definition of TNBC by current guidelines and subtypes identified by classical pathology 
The histological presentation of classical TNBCs is characterized by high mutational rate, high 
nuclear grade as well as the presence of necrosis and inflammatory infiltrates. However, 
these characteristics are observed in other high-grade breast carcinomas, as well. Therefore, 
in clinical practice, TNBC is currently defined by what it is not. TNBCs have in common that 
they are negative for the standard breast cancer markers and cannot be treated by 
established therapies such as endocrine and anti-HER2 therapy. This designation is helpful in 
the clinical setting since it provides a convenient name for this group of tumors for clinical 
decisions. Nevertheless, we cannot understand the true biology of these tumors using this 
definition.  
The updated guidelines on determination of hormone receptors and HER2 status in breast 
cancer have also influenced which tumors are designated triple-negative. The current 
guidelines35 have changed the cutpoint for ER and PR from 10% to 1%. This was based on 
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historical studies36 that have shown a benefit from endocrine therapy even with very low 
levels of hormone receptors. Gene expression analysis has shown that 76% of tumors with 
very low (1-9%) hormone receptor expression were ESR1 negative on the mRNA level, 48% 
were classified as basal-like and only 8% classified as luminal, all of them as luminal B.37 It is 
an open question if these tumors would also benefit from new therapeutic strategies that 
are currently developed for TNBC. The lower cutpoints for ER and PR therefore are useful to 
increase the number of patients eligible for endocrine therapy, but they might decrease the 
number of patients eligible for future TNBC-specific therapies, depending on the inclusion 
criteria in current clinical TNBC trials.  
Some subtypes of TNBC can be reliably identified upon histopathological evaluation of H&E 
slides, in particular tumors such as adenoid-cystic carcinomas (ADCC). These tumors are 
histologically similar to salivary gland tumors and show a typical MYB–NFIB gene fusion that 
is also found in salivary gland ADCCs.38,39 In contrast to classical TNBC, they have a low 
proliferation rate and a comparably good prognosis even with less aggressive treatment.40,41 
Several other rare subtypes of TNBC have been described, including low grade 
adenosquamous carcinoma42, fibromatosis-like metaplastic carcinoma,43 and secretory 
carcinoma44, and the published small cases-series suggest that these subtypes might also 
have an improved prognosis. Therefore, the identification of these subtypes is important for 
selection of less aggressive individual patient treatment strategies and these low-
proliferating tumors should not be included in TNBC clinical trials.  
 
Gene expression profiling strategies for classification of TNBC 
There have been several successful approaches to classify TNBC by gene expression profiling 
showing that basal markers, including keratin 5, EGFR and laminin, are typical for TNBC.45,46 
Basal-like tumors are enriched in TNBCs, but 21% of TNBC are not basal-like, and 31% of 
basal-like tumors are not triple-negative.47  
In a gene expression study specifically focused on TNBC, additional subtypes have been 
identified,48 including two basal-like (BL1 and BL2), an immunomodulatory (IM), a 
mesenchymal (M), a mesenchymal stem-like (MSL), and a luminal androgen receptor (LAR) 
type. Interestingly, important markers relevant for these additional subtypes derive from 
stromal cells, in particular fibroblasts and T-cells, which provides an additional molecular 
validation of the histopathological observation of increased tumor-infiltrating lymphocytes 
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in TNBC.47 Recently, these subtypes have been revised and limited to four distinct subtypes, 
i.e. BL1 and BL2, M, and LAR type TNBC.49 In a similar approach, Burstein et al.50 have 
described four subtypes: luminal/androgen receptor (LAR), mesenchymal (MES), basal-
like/immune-suppressed (BLIS) and basal-like/immune-activated (BLIA). TNBC subtypes have 
different response rates to neoadjuvant chemotherapy with highest response rates for BL1 
patients, and lower response rates in the BL2, LAR and M subtypes.49,51 The luminal 
androgen receptor subtype (approximately 16% of TNBC)49,52 might be an interesting 
candidate for an anti-androgen therapy, and a gene expression signature is under 
development to predict the response to AR inhibition.53 
Taken together, the gene expression analysis has shown that immune-markers, androgen-
receptor biology, mesenchymal phenotype, stem-cell markers and basal-markers are 
relevant for subclassification of TNBC. It should be noted that the transfer of TNBC subtyping 
to the daily clinical practice is not without challenges, due to the complex nature of the 
combined gene signatures. The original TNBC classifier developed by Lehmann et al.48 is 
based on the measurement of a total of 2188 genes, but recently it has been suggested that 
the number of genes could be reduced to 101 genes,54 which might be more manageable in 
the daily diagnostic practice. Currently, these molecular subtypes are not part of routine 
assessment of TNBC, but they provide a framework for the design of clinical studies that 
focus on the most relevant molecular alterations in the diverse TNBC subgroups. 
 
Tumor-infiltrating lymphocytes (TILs) as indicators of immunogenicity  
The tumor-associated immunological infiltrate is an important classical pathology parameter 
for TNBC. Traditionally, the subtype of medullary breast cancer shows a dominant 
lymphocytic infiltrate and a comparably good prognosis.55,56 The most important parameter 
for the clinical behavior of this tumor type is the lymphocytic infiltrate, and conventional 
invasive-ductal carcinomas with an increased lymphocytic infiltrate have a similarly good 
prognosis as the medullary group.57 Consequently, the current WHO classification has 
suggested that these tumors are not separate entities but represent the end of a spectrum 
of tumors that are characterized by an immunologically active tumor microenvironment.58 
Some candidate mechanisms for how an activated immunological microenvironment may be 
maintained by the tumor in subpopulations of TNBC have been proposed.59 
 11 
This is in line with a large number of studies investigating TILs in breast cancer.60 These 
studies have shown that TILs are linked to increased response to neoadjuvant chemotherapy 
in breast cancer.33 Neoadjuvant response is a well-established prognostic factor in triple-
negative breast cancer,4,11 and increased TIL levels have also been shown to be linked to 
improved prognosis in this subtype.34 ,61 
The focus on immune parameters is quite important for upcoming immunotherapy 
approaches including immune-checkpoint inhibitors, and the current data suggest that the 
modulation of the immune response might be able to increase therapy response in 
subgroups of TNBC.62 Interestingly, the immunosuppressive parameters PD1 and PD-L1 show 
a positive correlation with the other immunological markers as well as with tumor-
infiltrating lymphocytes.63  
 
BRCA1/2 mutation status and homologous recombination deficiency (HRD) 
The majority of hereditary (i.e. BRCA1/2 mutated) breast cancers show a triple negative 
profile.64 However, since BRCA-associated breast cancers are significantly less common 
compared to cases of TNBC, the majority of unselected TNBC are still wildtype for BRCA1/2.  
Tumors with BRCA1 or 2 mutations typically have a deficiency in homologous recombination 
(HRD) which means that damage to the DNA structure, in particular DNA double-strand 
breaks, and stalled or collapsed DNA replication forks, cannot be repaired properly. Over the 
life of the tumor, HDR leads to typical alterations in the DNA structure, which have been 
termed “genomic scars”. Typical characteristics of BRCA1/2 mutation associated genomic 
scars are large regions of loss-of-heterozygosity (LOH), increased numbers of telomeric allelic 
imbalances (NtAI) and large scale transitions (LST).65  
Recently, typical rearrangement signatures with high numbers of tandem duplications have 
been linked to basal-like TNBC with high HRD index and BRCA mutations.70 Interestingly, 
these alterations are typical for BRCA-mutant tumors but they have also been identified in 
tumors without a BRCA mutation.  
The currently described genomic scars have high sensitivity for BRCA1 or 2 mutation but 
appear to have poor specificity and positive predictive value for identifying tumor response 
that is specific to platinums rather than standard of care chemotherapy. Taken together this 
suggests that some BRCA wild-type tumors have a deficiency in homologous combination66 
but that biomarkers that have clinical utility must still be sought.  
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At present, even in the absence of a BRCA mutation a significant proportion of TNBCs show 
biologic similarities with BRCA-associated breast cancers. This phenomenon is commonly 
referred to as BRCAness.67 It is a current major research focus to define molecular markers 
of HDR that can be used to select patients whose tumors will develop specific responses to 
PARP inhibitor or platinum therapy.68 Similar to the immunological parameters, BRCA 
mutations and genomic scars are relevant molecular alterations for development and 
progression of TNBC, rather than specific markers for a defined subtype.  
 
Genomic analysis of somatic mutations and copy number changes in triple-negative 
tumors  
Comprehensive genomic investigations69,70 have provided extensive data on the mutational 
landscape of breast cancer, but they have not identified any tumor mutations that are 
characteristic for TNBC. The total number of non-synonymous somatic mutations measured 
by whole-exome sequencing in the TCGA database is higher in TNBC (median 49 mutations) 
compared to Luminal BC (median 27 mutations).71 Nevertheless, this mutational load in 
TNBC is still relatively low compared to malignant melanoma, NSCLC or MSI-colon cancer.72 
The main breast cancer mutations in PIK3CA and p53 are also the predominant mutations in 
TNBC, which higher mutations rated for p53 (50-80%) and slightly lower rates for PIK3CA 
(10-20%) compared to luminal tumors.73,70 PIK3CA mutations have been found to be 
increased in androgen-receptor positive TNBC.74  
It has been shown that copy number alterations (CNAs) and mutations are predominant in 
different subsets of tumors,75 and breast cancer, including TNBC, is a typical example of the 
C-class of tumors that show predominantly copy number alterations,76 but also a high rate of 
tp53 mutations.75 Fusion genes including genes encoding microtubule-associated serine-
threonine kinase (MAST) and members of the Notch family have been described in subsets 
of breast cancer.77 Different types of Notch gene rearrangement, which might be targetable 
by agents such as gamma-secretase inhibitors, are found in subsets of TNBC.  
 
New targeted therapeutic approaches in TNBC 
Immune checkpoint inhibitors  
There are several reasons why TNBC is regarded the optimal subtype of all breast cancers 
for immune checkpoint inhibition, with monoclonal antibodies including pembrolizumab 
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(targeting PD1) and atezolizumab (targeting PDL-1). TNBC has the highest mutational 
frequency of breast cancer subtypes, which might increase the chance of immunogenic 
mutations generating neoantigens.72,71 Furthermore, TNBC have increased levels of TILs and 
the prognostic role of TILs seems to be particularly strong among patients with TNBC.62  
In a phase-1b KEYNOTE-012 trial78 (table 2) patients with metastatic PD-L1-positive TNBC 
were treated with pembrolizumab. PDL-1 positivity (≥ 1% of tumor or stromal cells) by 
immunohistochemistry was observed in 58.6% of TNBC. Of the 32 patients that were 
registered onto the trial, 27 patients were evaluable for antitumor activity. An overall 
response rate of 18.5% was reported in association with a median time to response of 17.9 
weeks. Most importantly, the noted median duration of response was not yet reached, and 
a subset of patients also showed long-lasting responses. In the NCT01375842 phase 1a 
multicenter trial, 27 patients with pretreated metastatic PD-L1 positive TNBC were treated 
with PD-L1 inhibitor atezolizumab (MPDL3280A), leading to an ORR of 24%.79 
It is known that conventional chemotherapy can be immunogenic,80 which suggests a 
synergy between chemotherapy and immune therapy. In a phase 1b expansion trial81  
patients with metastatic TNBC with ≤ 3 prior lines of therapy were treated with 
atezolizumab in combination with nab-paclitaxel, followed by maintenance therapy with 
atezolizumab until loss of clinical benefit. Primary endpoints were safety and tolerability; 
secondary endpoints included clinical activity. A PD-L1 expression in at least ≥5% of TILs was 
a prerequisite for participation in the trial. 32 patients were evaluable for safety analysis at 
a median follow-up of 5.21 months. The most common treatment-related adverse-event 
was a decrease in neutrophil counts (occurring at grade 3-4 in 41% of cases). Overall 
response rates were 67%, 25%, and 29% for patients in first, second and third line, 
respectively. 
A corresponding phase trial III is currently recruiting patients world-wide. This trial 
(IMpassion130, NCT02425891) is a phase III, multicenter, randomized placebo-controlled 
study of atezolizumab in combination with nab-paclitaxel compared with placebo with nab-
paclitaxel for patients with first-line metastatic TNBC. In this trial, PD-L1 positivity is not 
required, since it is increasingly recognized that PD-L1 positivity might not predict an 
increased chance of response against PD-L1 inhibitors.  
These promising results have fostered initiation of a plethora of clinical trials including 
alternative PD1/PD-L1 inhibitors as well as combination regimens with tyrosine kinase 
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inhibitors, MEK inhibitors, PI3K inhibitors, anti-angiogenic agents or combination with other 
checkpoint inhibitors82 or co-stimulatory molecules. Table 3 lists selected clinical trials of 
PD1 or PD-L1 inhibition that are currently recruiting patients. 
 
PARP-inhibitors and other genetics-based therapy strategies 
Preclinical and clinical studies show that BRCA-mutated tumors have increased responses to 
PARP-inhibitor therapy, which can be elegantly explained by the concept of synthetic 
lethality.83 This concept implies that simultaneous loss of function of two genes, such as 
those caused by BRCA-mutation and PARP-inhibition, results in cell death, while loss of only 
one does not change cellular viability. One mechanistic model for synthetic lethality suggests 
that PARP inhibitors induce single-strand DNA breaks or trap PARP-1 on DNA causing DNA 
replication forks to arrest and progress to double-strand breaks. BRCA-deficient tumors are 
not able to repair these double-strand breaks and are therefore more sensitive to the PARP 
inhibitor. It should be noted that additional alternative mechanistic explanations have been 
suggested (for details see84).  
In the NCT00494234 non-randomized phase 2 trial patients with BRCA-mutated advanced 
breast cancer including those with TNBC were treated with olaparib 100mg or 400 mg twice 
daily (table 2). In particular in the group treated with 400mg, an objective response rate of 
41% was observed.85  
In the neoadjuvant I-SPY2 trial86, an adaptive trial design was used to evaluate the 
combination of the PARP inhibitor veliparib with carboplatin in addition to a standard 
anthracycline taxane neoadjuvant therapy. The addition of veliparib-carboplatin increased 
pCR rate in the TNBC group from 26% to 51%.  Due to the trial design it is not possible to 
attribute the increase in response to the PARP inhibitor or the platinum or a synergy in the 
combination.  
Based on this phase 2 results, the Brightness phase 387 trial is currently evaluating the 
addition of Carboplatin or carboplatin-veliparib to standard neoadjuvant therapy. The 
OlympiA trial88 is currently evaluating one year of olaparib as additional adjuvant therapy in 
patients with BRCA-mutations including those with high recurrence risk TNBC. An overview 
on the development of PARP inhibitors and additional clinical trials is given in a 
comprehensive review by Sonnenblick et al.89 
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In addition to agents focusing on PARP inhibition, clinical trials are ongoing that target other 
genomic alterations, including comprehensive trial programs such as SAFIR02 
(NCT02299999)  and the Aurora90 initiative.  
It has been shown that 4% of TNBC have an amplification of FGFR-291 and that FGFR 
signaling is involved in growth regulation of TNBC in preclinical models.92 Based on these 
findings, clinical trials of FGFR inhibition have been conducted in TNBC and other types of 
breast cancer (Overview:93). A recent phase 2 study94 included breast carcinomas with FGFR-
1 amplification and gastric carcinomas with FGFR2 amplification. In this trial 1 of 8 breast 
cancer patients (12.5%) showed a response to the FGFR inhibitor AZD4547, while 3 of 9 
gastric cancer patients (33%) had a response. The responding patients were characterized by 
high levels of gene amplification, which is relatively rare in breast cancer. 
The NOTCH signaling pathway is involved in regulation of stem cell renewal.95 Alterations of 
NOTCH receptors including rearrangements,96 fusion genes77 as well as mutations97 have 
been observed in subsets of TNBCs and have been linked to increased response to gamma-
secretase inhibitors. First results of phase 1 dose-finding studies of gamma-secretase 
inhibitors in TNBC have recently been published.98 
 
 
Bevacizumab  
Bevacizumab has been shown to increase pCR rates in triple-negative breast cancer in the 
GeparQuinto trial99,100 (Bev: 36% vs. control: 21%; ypT0ypN0), the CALGB 40603 trial21,22 
(59% vs. 48%; pT0/is), the SWOG S0800101 trial (59% vs. 29%; ypT0/isyN0) and the ARTemis 
trial102 (45% vs. 31%, ypT0/isyN0). In contrast, in the NSABP-B40 trial, the increased pCR rate 
with bevacizumab was observed only in the hormone receptor positive subgroup (23% vs. 
15%),103 but not in the TN-subgroup (52% vs. 47%). Up to now, most neoadjuvant trials have 
not reported a survival advantage of the bevacizumab treatment. The exception is NSABP-
B40, where a significant overall but not disease-free survival benefit that was observed.104 In 
the adjuvant BEATRICE study, no difference in invasive-disease free survival and in overall 
survival was reported with the addition of bevacizumab to adjuvant chemotherapy.105 It has 
been suggested that the current data does not allow the use of bevacizumab in early breast 
cancer, but that the combined evaluation of the neoadjuvant trials as well as biomarker-
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based stratifications might allow a better understanding of the clinical benefit of 
bevacizumab in defined subgroups.106 
 
Androgen receptor inhibitors  
There is a large and increasing body of evidence suggesting a potential role for androgen 
receptor (AR) targeting in a subset of breast cancer patients. In a recent meta-analysis of 
thirteen relevant studies including 2826 patients with TNBC an AR positivity rate of 24.4% 
was observed.52 Most importantly, AR seems to represent a potential therapy target for 
endocrine therapy among patients with TNBC. Early study results suggest activity of AR 
inhibition in AR positive TNBC. Gucalp et al. examined clinical activity of the AR antagonist 
bicalutamide in patients with ER/PR-negative advanced breast cancer with >10% 
immunohistochemical nuclear staining for AR. Of 424 patients that were screened for AR 
positivity, 12% tested AR-positive. The authors reported a 6-month clinical benefit rate of 
19% and a median PFS of 12 weeks.107  
Bonnefoi and colleagues reported the results of a phase II clinical trial of Abiraterone 
acetate (AA) in 30 women with centrally reviewed AR-positive (≥10% by 
immunohistochemistry, IHC), but otherwise triple-negative heavily pretreated metastatic or 
inoperable locally advanced BC. An ORR of 6.7 and a median PFS of 2.8 months was 
observed. Side effects included fatigue, hypertension, hypokalaemia and nausea.108 In the 
MDV3100-11 phase 2 trial109 118 patients with AR positive TNBC were treated with the AR 
inhibitor enzalutamide, and 57 patients were evaluable for clinical benefit. At 16 weeks, a 
clinical benefit rate of 35% was observed. The observed benefit appeared higher in patients 
with tumors that were positive for an AR-related gene signature. 
Additional clinical trial concepts for androgen receptor inhibitors include combination with 
palbociclib (NCT02605486) 110 as well as PIK3CA inhibitors.111 Several additional clinical 
trials112 of androgen receptor inhibitors are currently ongoing that cannot be discussed here 
in more detail. 113 
 
Towards a unified model of TNBC biology? 
In conclusion, the knowledge about triple-negative breast cancer has increased during the 
last years, and we are observing relevant response signals in clinical trials. It should be 
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emphasized that none of the new therapies has been finally evaluated in phase 3 trials and 
that still chemotherapy is the only validated therapy option for treatment of TNBC in clinical 
practice. Nevertheless, the current results are promising because they are based on 
hypotheses that are derived from systematical evaluations of biological alterations in these 
tumors, including a deficiency in homologous recombination, an increased immunological 
infiltrate and an expression of androgen receptors. These alterations are typically only 
observed in all subgroups of TNBC and they are also not exclusive for TNBC. They should be 
seen as independent biological factors that form the basis for therapeutic interventions. The 
final biological model of TNBC will be determined by the results of the ongoing clinical trials 
and should focus on those markers that identify both biologically and clinically relevant 
subtypes. 
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Figure legend: 
 
Figure 1: Overview on relevant molecular alterations in triple-negative breast cancer 
measured by different methodological approaches, including gene-expression profiling, 
classical histopathology and genomic alterations. Despite the different classification systems 
derived from the different approaches, there are common themes emerging. These themes 
include an increased immunological infiltrate (red), a high proliferation rate (green) , an 
expression of androgen receptors (blue) and a homologous recombination deficiency 
(orange). The color coding indicates that these themes are observed in parallel in different 
classification approaches. Based on these molecular results, at least 4 important therapy 
strategies for TNBC are emerging, which are currently tested in clinical studies. 
 
Figure 1: 
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Table 1: Chemotherapy of TNBC – classical and new approaches: overview on relevant 
meta-analyses and clinical trials 
Trial  Clincial cohort and 
therapeutic 
intervention 
Main result Reference  
Selected meta-analyses 
Conventional 
adjuvant 
chemotherapy 
EBCTCG 
Metaanalysis of 123 
clinical studies 
(n=101000), different 
types of adjuvant 
chemotherapy 
Anthracycline-taxane therapy; 30% 
risk reduction in all major subgroups, 
including ER-negative tumors 
EBCTCG, 
Lancet 201210 
Conventional 
neoadjuvant 
chemotherapy 
CTNeoBC 
12 clinical studies 
(n=11955), different 
types of neoadjuvant 
chemotherapy 
Association between pCR and long-
term outcomes was particularly large 
in TNBC 
Cortazar et al, 
Lancet 201411 
Dose-dense 
adjuvant 
chemotherapy 
Metaanalysis of 10 
clinical studies 
(n=3337), Dose-dense 
vs.convent. chemoTx 
Dose-dense chemotherapy results in 
better overall and disease-free 
survival, particularly in women with 
hormone receptor-negative BC 
Bonilla et al. 
JNCI 2010 15 
 
Platinum-therapy 
GEICAM/2006-03 
Randomized 
phase 2 
neoadjuvant 
multicenter study 
NCT00432172 
Operable TNBC, basal-
like subtype (negative 
for: ER,PR,HER2; 
positive for CK5/6+ or 
EGFR+) 
Neoadjuvant; 4 cycles 
EC followed by 
docetaxel (EC-D) vs 
docetaxel+carboplatin 
(EC-DCb) (n=94) 
 
No difference in efficacy. pCR 
(breast) 35% with EC-D vs. 30% with 
EC-DCb 
Alba et al. 
Breast Cancer 
Res Treat. 
2012 23 
GeparSixto 
Randomized 
neoadjuvant 
phase 2 trial 
NCT01426880 
N=595, stage 2-3 TNBC 
or HER2+ BC, 
weekly paclitaxel and 
liposomal doxorubicin, 
with or without weekly 
carboplatin, all TNBC 
patients received 
bevacizimab 
Therapy response: TNBC subgroup: 
pCR rate increased from 37% to 53% 
with carboplatin; 
Carboplatin effect was stronger in 
patients without BRCA mutations 
Survival: DFS in TNBC 85.8% with 
carboplatin and 76.1% without 
(hazard ratio = 0.56, P = .0350). 
 
Von 
Minckwitz et 
al. Lancet 
Oncol, 2014 
17  
von 
Minckwitz et 
al. 2015 San 
Antonio 
Breast Cancer 
Symposium,  
Abstract S2-
04. 18 
CALGB 40603 
Randomized 2x2 
phase 2 trial 
 
Stage 2-3 breast cancer 
(ER and PR>=10%, 
HER2 neg),  (n=443);  
Neoadjuvant paclitaxel 
vs. paclitaxel+ 
bevacizumab vs. 
paclitaxel+ carboplatin 
Therapy response: addition of either 
carboplatin or bevacizumab to NACT 
increased pCR rates; 
Survival: no outcome differences 
between therapy groups 
Sikov et al., J. 
Clin. Oncol., 
2015 21 
Sikov WM, 
2015 San 
Antonio 
Breast Cancer 
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vs. paclitacel+ 
carboplatin+ 
Bevacizumab 
 
Symposium, 
Abstract S2-
05. 22 
 
TNT trial 
Randomized 
phase 3 trial 
NCT00532727 
Recurrent locally 
advanced or metastatic 
TNBC, n=376  
Carboplatin vs. 
docetaxel 
No difference in response rates to 
therapy arms in the complete cohort; 
Increased response rate to 
carboplatin (68% vs. 33% with 
docetaxel) in the subgroup of 
BRCA1/2 mutated tumors: 
HRD-assay: increased score linked to 
increased response in both therapy 
arms; 
PAM50 assay, non-basal subtype: 
higher response to docetaxel 
compared to carboplatin 
Tutt et al.  
2014 San 
Antonio 
Breast Cancer 
Symposium, 
Abstract S3-
01 Error! Bookmark 
not defined. 
NCT01611727 
Phase 2 non-
randomized 
single-arm trial 
Metastatic breast 
cancer in patients with 
BRCA mutation (n=20) 
Overall response rate: 80%; median 
time to progression:12 months. 
Byrski et al. 
Breast Cancer 
Res. 2012 27 
CBCSG006 
open-label 
randomized 
phase 3 
metastatic TNBC 
(n=240) 
cisplatin plus 
gemcitabine vs. 
paclitaxel plus 
gemcitabine  
Improved progression-free survival 
with cisplatin/gemzitabine therapy in 
unselected advanced TNBC 
Hu et al.24 
PrECOG 0105  
non-randomized 
single-arm 
neoadjuvant 
phase 2 study 
NCT00813956 
 stage 1-3A BC, either 
HER2neg; ER/PR>=5%; 
or BRCA1/2 mutated, 
any ER/PR, HER2-24% 
with BRCA1/2 mutation 
Neoadjuvant 
gemcitabine, 
carboplatin and 
iniparib (BSI-201) 
N=80 in intention-to-
treat (ITT) cohort with 
six cycles 
Biomarkers: BRCA 
mutation analysis; 
HRD-LOH score 
36% pCR in ITT group; 
higher pCR in: 
BRCA1/2 mutated tumors (47%): 
TNBC BRCA1/2 mutated tumors 
(56%); 
higher HDR-LOH observed scores in 
responders 
 
Comment: This trial used iniparib, 
which was later shown not to be a 
PARP inhibitor, therefore it is 
summarized here as a platinum-
trial.89 
Telli, JCO 
2015 28 
TBCRC009 
Phase 2 non-
randomized 
single-arm 
metastatic TNBC 
(n=86), cisplatin or 
carboplatin 
monotherapy 
Objective response rate: 
26% (all patients); 
55% (pts with BRCA1/2 mutation); 
20% (pts without BRCA1/2 
mutation); 
increased HRD score in responding 
patients (whole cohort and 
subcohort without BRCA mutation)  
Isakoff, J. 
Clin. Oncol. 
2015 29Error! 
Bookmark not 
defined. 
Other chemotherapy approaches - postneoadjuvant therapy or adjuvant metronomic strategies 
CREATE-X Patients with HER2neg Interim analysis with improved Toi M, 2015 
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UMIN000000843 breast cancer with non-
pCR in the neoadjuvant 
setting, adjuvant 
capecitabine vs no 
adjuvant therapy, 
n=910, 37% TNBC 
survival with post-NACT 
capecitabine; 
2-year DFS 87% with capecitabine vs. 
81% in control arm 
TNBC subgroup : HR of 0.58 in favor 
of postneoadjuvant capecitabine  
San Antonio 
Breast Cancer 
Symposium, 
Abstract S1-
07. 31 
IBCSG 22-00 
Randomized 
phase 3  
NCT00022516 
ER/ PR neg BC (both 
>=10%), any HER2 
status, completed 
surgery and adjuvant 
chemotherapy; 
randomized to 12 
month metronomic 
cyclophosphamide  
methotrexate 
maintenance vs no 
maintenance therapy, 
n=1086 
No significant reduction in DFS in the 
complete study cohort and in the 
TNBC group (n=814); 
Subanalysis for node-positive TNBC 
(n=340) showed a non-significant 
trend towards improved DFS in the 
experimental arm 
Colleoni M et 
al., J Clin 
Oncol. 2016. 
32 
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Table 2: Targeted therapy of TNBC – overview on selected clinical trials of immune 
checkpoint inhibitors, PARP inhibitors, bevacizumab and anti-androgens 
 
Trial  Clincial cohort and 
therapeutic intervention 
Main result Reference 
Immune checkpoint inhibitors 
KEYNOTE-012 
nonrandomized, 
multicohort, 
phase Ib study 
NCT01848834 
Metastatic PD-L1-positive 
TNBC 
(all therapy lines) 
the PD-L1 inhibitor 
pembrolizumab given 
intravenously at 10 mg/kg 
every 2 weeks 
32 patients with TNBC 
enrolled, 28 pts. wiith 
evaluable response 
Efficacy: overall response rate: 
18.5% 
median time to response: 17.9 
weeks 
Safety: 15.6% incidence of grade 
3 to 5 treatment-related AEs 
 
Nanda et al. J 
Clin Oncol. 
2016   78  
NCT01375842 
multicenter Phase 
Ia study 
 
pts with pretreated 
metatatic PD-L1 positive 
TNBC enrolled (n=27) 
received the PD-L1 inhibitor 
atezolizumab (MPDL3280A) 
at 15 mg/kg, 20 mg/kg or 
1200 mg flat dose IV q3w. 
 
Efficacy: unconfirmed RECIST 
ORR 24%; 
 
Safety: Grade 3-5 related AE in 
11% of pts 
Emens et al. 
2015 AACR 
Annual 
Meeting. 
Abstract 
2859. 79  
GP28328 
Phase Ib 
multicenter 
NCT01633970 
 
  
metastatic TNBC treated 
with ≤ 3 prior lines of 
therapy (n=32) 
atezolizumab (MPDL3280A; 
800 mg q2w (d1,15)) in 
combination with nab-
paclitaxel (125 mg/m2 q1w 
(d1,8,15) q3 of 4 weeks) 
Data from ongoing study 
presented at SABCS 2015: 
Efficacy: overall response rates 
were 
1st line: 67% 
2nd line 25% 
3rd line 29% 
all patients: 42% 
Safety: 56% Grade 3-4 AEs 
Adams et al. 
2015 San 
Antonio 
Breast Cancer 
Symposium; 
Abstract P2-
11-06 81 
Androgen receptor inhibitors 
UCBG 12-1 
Single arm open 
label multicenter 
Phase II 
NCT01842321 
metastatic or locally 
advanced, triple negative 
and AR-positive BC (n=30) 
abiraterone acetate (AA, 
1000 mg) once a day + 
prednisone (5 mg) twice a 
day 
Clinical benefit rate (CBR) 20.0% 
[95%CI 7.7%-38.6%] 
ORR 6.7% (0.8%-22.1%) 
median PFS 2.8 months (1.7%-
5.4%). 
 
Safety: 14.7% grade 3 AEs 
Bonnefoi et 
al.,  Ann 
Oncol. 2016 
108 
MDV3100-11 
phase 2 study  
NCT01889238 
 
evaluating single agent  
enzalutamide in advanced 
AR+ TNBC (n=118 treaten, 
n=75 evaluated for 
response) 
evaluation of AR signature 
as possible biomarker 
Clinical benefit rate (16 wks): 
35% (all pts) 
39% (AR signature +) 
 
Safety: 5% AE >= grade 3 
Traina et al., 
ACO 2015, 
Abstr 1003 109 
TBCRC 011 AR pos. ER/PRneg. Efficacy: 6 month CBR: 19% Gucalp 
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Phase 2 study 
NCT00468715 
metastatic BC 
Bicalutamide 150 mg orally 
N=28 treated; N026 for 
resonse evaluation 
Median PFS 12 weeks 
 
Safety: 14% grade 3 AEs 
Clinical 
Cancer Res 
2013 107 
PARP inhibitor therapy 
NCT00494234 
Phase 2 
multicenter trial 
Recurrent advanced breast 
cancer with BRCA1/2 
mutations 
Subcohort 1 (n=27): 
olaparib (AZD2281) 400mg 
twice daily, 50% TNBC 
Subcohort 2 (n=27): 
olaparib 100mg twice daily, 
64% TNBC 
Objective response rates: 
41% (subcohort 1) 
22% (subcohort 2) 
 
Safety: grade 3-4 SAEs in 24% of 
pts. 
Tutt et al. 
2010 85 
I-SPY 2  
multicenter 
neoadjuvant, 
adaptively 
randomized 
phase 2 study 
NCT01042379 
Stage 2-3 breast cancer, 
paclitaxel, doxorubicin, 
cyclophosphamide 
with or without veliparib 
(ABT888)-carboplatin 
(n=116, all TNBC) 
 
 
Estimated pCR rates (Bayesian 
predicted probability) higher for 
veliparib–carboplatin Tx (51% vs. 
26%); 
Probability of success in phase 3 
trial: 88% in TNBC ; 
Higher rate of toxic effects in 
veliparib-carboplatin group 
Rugo et al., 
NEJM 2016 86 
Brightness 
Phase 3 
randomized 
multicenter study 
NCT02032277 
 
Planned N=624, T2-T4 
TNBC 
Standard NACT vs. 
NACT+carboplatin vs. 
NACT+carboplatin+veliparib  
Study under follow-up von 
Minckwitz G, 
et al. ASCO 
2014; abstr 
TPS1149 87 
OlympiA 
Phase 3 
randomized 
multicenter trial 
NCT02032823 
 
adjuvant olaparib in high –risk 
TNBC and ER+/HER2-ve BC 
with germline BRCA1/2 
mutation; 
planned n=1500 
Recruitment ongoing Tutt et al. 
ASCO 2015; 
abstr 
TPS1109 88 
Bevacizumab 
GeparQuinto 
Neoadjuvant 
phase 3 
multicenter study 
NCT00567554 
 
Untreated HER2-neg breast 
cancer, (n=1948, TNBC 
subgroup n=663); 
neoadjuvant EC-D with or 
without bevacizumab; 
No postoperativ bev; bev 
discontinued in non-
responders after 4 cycles 
EC 
Therapy response: 
pCR rates (bev- vs. control-arm): 
all pts: 18% vs 15% (ns) 
TNBC: 39% vs. 28% (p=0.003) 
HR-pos BC: no difference 
Survival: no difference between 
Bev-arm and control 
von 
Minckwitz et 
al NEJM 2015 
99 
von 
Minckwitz et 
al. Ann. 
Oncol. 2014. 
100 
NSABP-B40 
Neoadjuvant 
phase 3 
multicenter trial 
3x2 factorial 
design 
NCT00408408 
Primary operable HER2neg 
BC; 
Three different types of 
neoadjuvant 
chemotherapy, all with or 
without bevacizumab, 
Bev continued 
Therapy response: 
pCR rates (bev- vs. control-arm): 
all pts: 35% vs 28% (p=0.02) 
TNBC: 52% vs. 47% (p=ns) 
HR-pos BC: 23% vs. 15% 
(p=0.007) 
Survival OS: improved overall 
Bear et al, 
NEJM 2012 103  
Bear et al, 
Lancet 
oncology 
2015 104 
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postoperatively 
N=1206, 41% TNBC 
survival with bev (HR 0.65, 
p=0.004) 
Survival DFS: not significant, but 
trend to better survival with bev 
(p=0.06) 
Survival effect mainly in the 
HRpos subcohort 
SWOG S0800 
Randomized 
neoadjuvant 
phase 2 study 
NCI 
CDR0000636131 
Stage 2b-3c untreated 
HER2-neg Breast cancer; 
n=212;  
nab-paclitaxel with 
concurrent bevacizumab 
followed by doxorubicin-
cyclophosphamide (AC) vs. 
AC followed by nab-
paclitaxel with concurrent 
bevacizumab vs. AC 
followed by NAB-paclitaxel 
Therapy response: pCR rates 
(bev- vs. control-arm): 
all pts: 36% vs 21% (p=0.019) 
TNBC: 59% vs. 29% (p=0.014) 
HR-pos BC: no difference 
Survival: no difference between 
Bev-arm and control, trend in 
favor of bev in TNBC (p=0.06) 
Nahleh ZA, 
Breast cancer 
research 
treatment, 
2016 101 
CALBG 40603 See above table 1 for 
details 
Therapy response: addition 
bevacizumab to NACT increased 
pCR rates; 
Survival: no outcome differences 
between therapy groups 
Sikov et al., J. 
Clin. Oncol., 
2015 21 
Sikov WM, 
2015 San 
Antonio 
Breast Cancer 
Symposium. 
Abstract S2-
05. 22 
ARTemis 
Neoadjuvant 
phase 3 trial 
NCT01093235 
HER2neg early BC 
D-FEC neoadjuvant therapy 
with or without 
bevacizumab; n=800; 
31% ERneg 
Therapy response: pCR rates 
(bev- vs. control-arm): 
all pts: 22% vs 17% (p=0.03) 
numerically stronger effect in 
ERneg and ER-weakly pos 
subgroups. 
No p-values for ER subgroups 
reported. 
Currently no survival data. 
Earl et al. 
Lancet Oncol. 
2015 102 
BEATRICE 
Randomized 
multicenter 
adjuvant phase 3 
trial 
NCT00528567 
Operable HER2neg primary 
BC; Chemotherapy with or 
without bevacizumab; 
n=1290 
No difference in invasive 
disease-free survival or in overall 
survival between treatment 
groups 
Cameron et 
al. Lancet 
Oncol. 2013 
105 
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Table 3: selected clinical trials of PD1 or PD-L1 inhibition that are currently recruiting 
patients 
Trial number  
(Trial name) 
Indication Phase Design 
NCT02513472 MBC, 
(1st to 3rd 
line) 
Phase 1b/2 Eribulin + Pembrolizumab* (single-arm) 
NCT02499367 
(TONIC) 
MBC 
(2nd to 4th 
line) 
Phase 2 Nivolumab** alone vs. 
nivolumab + 
 doxorubicin vs. 
 cyclophosphamide vs.  
 radiation vs. 
 cisplatin 
(five arms, open-label) 
NCT02447003 
(KEYNOTE-086) 
MBC 
(all lines) 
Phase 2 Pembrolizumab 
(single-arm) 
NCT02819518 
(KEYNOTE-355) 
   Part 1 
 
 
   Part 2 
MBC / LABC 
(1st line) 
 
 
 
MBC / LABC 
(1st line) 
Phase 3 
 
 
 
 
Phase 3 
Pembrolizumab + 
 Nab-Paclitaxel vs. 
 Paclitaxel vs. 
 Gemcitabine/Carboplatin 
 
Pembrolizumab + chemotherapy 
Vs. pembrolizumab + placebo 
    
NCT02555657 
(KEYNOTE-119) 
MBC 
(2nd or 3rd 
line) 
Phase 3 Pembrolizumab vs. 
Physian’s choice (capecitabine, eribulin, 
gemcitaine or vinorelbine) 
NCT02425891 
(IMpassion130) 
MBC 
(1st line) 
Phase 3 Nab-paclitaxel + azetolizumab vs. Nab-
paclitaxel + placebo 
NCT02489448 EBC 
(neoadjuvant) 
Phase 1/2 MEDI4736 *** + weekly Nab-Paclitaxel 
followed by dose-dense doxorubicin / 
cyclophosphamide  
(single arm) 
NCT02530489 EBC 
(neoadjuvant) 
Phase 2 Azetolizumab + Nab-Paclitaxel 
NCT02620280 
(NeoTRIPaPDL1) 
EBC 
(neoadjuvant) 
Phase 3 Carboplatin + Nab-Paclitaxel + 
Azetolizumab vs. 
Carboplatin + Nab-Paclitaxel 
(open-label) 
NCT02685059 
GeparNuevo 
EBC, TNBC 
(neoadjuvant) 
Phase 2 Epirubicin + Cyclophosphamide + NAB-
Paclitaxel + Durvalumab (MEDI4736) 
vs. Epirubicin + Cyclophosphamide + 
NAB-Paclitaxel + placebo 
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